| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Valéria Almeida, Fernanda F Peres, Raquel Levin, Mayra A Suiama, Mariana B Calzavara, Antônio W Zuardi, Jaime E Hallak, José A Crippa, Vanessa C Abíli. Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: the SHR strain. Schizophrenia research. vol 153. issue 1-3. 2015-04-22. PMID:24556469. |
effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: the shr strain. |
2015-04-22 |
2023-08-12 |
rat |
| Valéria Almeida, Fernanda F Peres, Raquel Levin, Mayra A Suiama, Mariana B Calzavara, Antônio W Zuardi, Jaime E Hallak, José A Crippa, Vanessa C Abíli. Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: the SHR strain. Schizophrenia research. vol 153. issue 1-3. 2015-04-22. PMID:24556469. |
studies have suggested that the endocannabinoid system is implicated in the pathophysiology of schizophrenia. |
2015-04-22 |
2023-08-12 |
rat |
| Valéria Almeida, Fernanda F Peres, Raquel Levin, Mayra A Suiama, Mariana B Calzavara, Antônio W Zuardi, Jaime E Hallak, José A Crippa, Vanessa C Abíli. Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: the SHR strain. Schizophrenia research. vol 153. issue 1-3. 2015-04-22. PMID:24556469. |
our results indicate that the schizophrenia-like behaviors displayed by shr are differently altered by cannabinoid and vanilloid drugs when compared to control animals and suggest the endocannabinoid and the vanilloid systems as a potential target for the treatment of schizophrenia. |
2015-04-22 |
2023-08-12 |
rat |
| P J Robson, G W Guy, V Di Marz. Cannabinoids and schizophrenia: therapeutic prospects. Current pharmaceutical design. vol 20. issue 13. 2015-02-20. PMID:23829368. |
cannabinoids and schizophrenia: therapeutic prospects. |
2015-02-20 |
2023-08-12 |
Not clear |
| Matthijs G Bossong, Gerry Jager, Sagnik Bhattacharyya, Paul Alle. Acute and non-acute effects of cannabis on human memory function: a critical review of neuroimaging studies. Current pharmaceutical design. vol 20. issue 13. 2015-02-20. PMID:23829369. |
learning and memory deficits are core symptoms of psychiatric and neurological disorders such as schizophrenia and alzheimer's disease, and may also be related to endocannabinoid dysfunction in these disorders. |
2015-02-20 |
2023-08-12 |
human |
| Hannah Steeds, Robin L Carhart-Harris, James M Ston. Drug models of schizophrenia. Therapeutic advances in psychopharmacology. vol 5. issue 1. 2015-02-05. PMID:25653831. |
in this paper, we selectively review findings from dopaminergic, glutamatergic, serotonergic, cannabinoid, gaba, cholinergic and kappa opioid pharmacological drug models to evaluate their similarity to schizophrenia. |
2015-02-05 |
2023-08-13 |
Not clear |
| Rodrigo Ferretjans, Salvina Maria de Campos, Rafael Ribeiro-Santos, Fernanda Carneiro Guimarães, Keliane de Oliveira, Ana Cecília Alves Cardoso, Marcio Sobreira Araújo, Andrea Teixeira-Carvalho, Olindo Assis Martins-Filho, Antonio L Teixeira, João V Salgad. Cognitive performance and peripheral endocannabinoid system receptor expression in schizophrenia. Schizophrenia research. vol 156. issue 2-3. 2015-01-20. PMID:24853061. |
cognitive performance and peripheral endocannabinoid system receptor expression in schizophrenia. |
2015-01-20 |
2023-08-13 |
human |
| Rodrigo Ferretjans, Salvina Maria de Campos, Rafael Ribeiro-Santos, Fernanda Carneiro Guimarães, Keliane de Oliveira, Ana Cecília Alves Cardoso, Marcio Sobreira Araújo, Andrea Teixeira-Carvalho, Olindo Assis Martins-Filho, Antonio L Teixeira, João V Salgad. Cognitive performance and peripheral endocannabinoid system receptor expression in schizophrenia. Schizophrenia research. vol 156. issue 2-3. 2015-01-20. PMID:24853061. |
the objective of this study was to compare levels of peripheral endocannabinoid receptor expression in patients with schizophrenia and healthy subjects and find evidence of association between peripheral expression of those receptors and cognitive performance. |
2015-01-20 |
2023-08-13 |
human |
| Jana Kucerova, Katarina Tabiova, Filippo Drago, Vincenzo Mical. Therapeutic potential of cannabinoids in schizophrenia. Recent patents on CNS drug discovery. vol 9. issue 1. 2014-12-22. PMID:24605939. |
therapeutic potential of cannabinoids in schizophrenia. |
2014-12-22 |
2023-08-12 |
Not clear |
| Jana Kucerova, Katarina Tabiova, Filippo Drago, Vincenzo Mical. Therapeutic potential of cannabinoids in schizophrenia. Recent patents on CNS drug discovery. vol 9. issue 1. 2014-12-22. PMID:24605939. |
increasing evidence suggests a close relationship between the endocannabinoid system and schizophrenia. |
2014-12-22 |
2023-08-12 |
Not clear |
| Jana Kucerova, Katarina Tabiova, Filippo Drago, Vincenzo Mical. Therapeutic potential of cannabinoids in schizophrenia. Recent patents on CNS drug discovery. vol 9. issue 1. 2014-12-22. PMID:24605939. |
hence, the endocannabinoid system is strongly involved in neuropsychiatric disorders, such as schizophrenia. |
2014-12-22 |
2023-08-12 |
Not clear |
| Matthijs G Bossong, J Martijn Jansma, Sagnik Bhattacharyya, Nick F Ramse. Role of the endocannabinoid system in brain functions relevant for schizophrenia: an overview of human challenge studies with cannabis or ∆9-tetrahydrocannabinol (THC). Progress in neuro-psychopharmacology & biological psychiatry. vol 52. 2014-12-12. PMID:24380726. |
role of the endocannabinoid system in brain functions relevant for schizophrenia: an overview of human challenge studies with cannabis or ∆9-tetrahydrocannabinol (thc). |
2014-12-12 |
2023-08-12 |
human |
| Matthijs G Bossong, J Martijn Jansma, Sagnik Bhattacharyya, Nick F Ramse. Role of the endocannabinoid system in brain functions relevant for schizophrenia: an overview of human challenge studies with cannabis or ∆9-tetrahydrocannabinol (THC). Progress in neuro-psychopharmacology & biological psychiatry. vol 52. 2014-12-12. PMID:24380726. |
however, before new research can focus on potential treatments that work by manipulating the endocannabinoid system, it needs to be elucidated how this system is involved in symptoms of schizophrenia. |
2014-12-12 |
2023-08-12 |
human |
| Matthijs G Bossong, J Martijn Jansma, Sagnik Bhattacharyya, Nick F Ramse. Role of the endocannabinoid system in brain functions relevant for schizophrenia: an overview of human challenge studies with cannabis or ∆9-tetrahydrocannabinol (THC). Progress in neuro-psychopharmacology & biological psychiatry. vol 52. 2014-12-12. PMID:24380726. |
these similarities in brain function between intoxicated healthy volunteers and schizophrenia patients provide an argument for a role of the endocannabinoid system in symptoms of schizophrenia, and further emphasize this system as a potential novel target for treatment of these symptoms. |
2014-12-12 |
2023-08-12 |
human |
| Brittany Draycott, Michael Loureiro, Tasha Ahmad, Huibing Tan, Jordan Zunder, Steven R Laviolett. Cannabinoid transmission in the prefrontal cortex bi-phasically controls emotional memory formation via functional interactions with the ventral tegmental area. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 34. issue 39. 2014-11-25. PMID:25253856. |
disturbances in cortical cannabinoid cb1 receptor signaling are well established correlates of various neuropsychiatric disorders, including depression and schizophrenia. |
2014-11-25 |
2023-08-13 |
rat |
| J R Spencer, T W Chohan, T Karl, J C Arnol. Female neuregulin 1 heterozygous mice require repeated exposure to Δ⁹-tetrahydrocannabinol to alter sensorimotor gating function. Pharmacopsychiatry. vol 46. issue 7. 2014-11-15. PMID:24105081. |
the schizophrenia susceptibility gene neuregulin 1 (nrg1) confers vulnerability to the neurobehavioural eff ects of cannabinoids differently across sexes. |
2014-11-15 |
2023-08-12 |
mouse |
| Mathieu Verdurand, Victoria S Dalton, Vu Nguyen, Marie-Claude Grégoire, David Zahra, Naomi Wyatt, Leena Burgess, Ivan Greguric, Katerina Zavitsano. Prenatal poly I:C age-dependently alters cannabinoid type 1 receptors in offspring: a longitudinal small animal PET study using [(18)F]MK-9470. Experimental neurology. vol 257. 2014-08-13. PMID:24825369. |
evidence suggests that there is a link between the endocannabinoid system (ecs) and neuropsychiatric illnesses, including schizophrenia. |
2014-08-13 |
2023-08-13 |
rat |
| Huibing Tan, Tasha Ahmad, Michael Loureiro, Jordan Zunder, Steven R Laviolett. The role of cannabinoid transmission in emotional memory formation: implications for addiction and schizophrenia. Frontiers in psychiatry. vol 5. 2014-07-29. PMID:25071606. |
the role of cannabinoid transmission in emotional memory formation: implications for addiction and schizophrenia. |
2014-07-29 |
2023-08-13 |
Not clear |
| Huibing Tan, Tasha Ahmad, Michael Loureiro, Jordan Zunder, Steven R Laviolett. The role of cannabinoid transmission in emotional memory formation: implications for addiction and schizophrenia. Frontiers in psychiatry. vol 5. 2014-07-29. PMID:25071606. |
considerable evidence has demonstrated that cannabinoid transmission functionally interacts with dopamine (da), a neurotransmitter system that is of exceptional importance for both addictive behaviors and the neuropsychopathology of disorders like schizophrenia. |
2014-07-29 |
2023-08-13 |
Not clear |
| Evan Leibu, Amir Garakani, Daniel P McGonigle, Lauren S Liebman, Daniella Loh, Ethan O Bryson, Charles H Kellne. Electroconvulsive therapy (ECT) for catatonia in a patient with schizophrenia and synthetic cannabinoid abuse: a case report. The journal of ECT. vol 29. issue 4. 2014-07-17. PMID:23670023. |
electroconvulsive therapy (ect) for catatonia in a patient with schizophrenia and synthetic cannabinoid abuse: a case report. |
2014-07-17 |
2023-08-12 |
Not clear |